ROCO
4129
Market cap313mUSD
Nov 12, Last price
125.50TWD
Name
United Orthopedic Corp
Chart & Performance
P/E
21.48
P/S
2.11
EPS
5.84
Div Yield, %
3.19%
Shrs. gr., 5y
1.65%
Rev. gr., 5y
13.68%
Revenues
4.65b
+18.40%
Net income
456m
+18.80%
CFO
717m
+80.03%
Dividend
Jul 18, 20244.00266 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
United Orthopedic Corporation engages in the research, development, manufacture, and sale of orthopedic implants and surgical instruments. The company offers artificial hip joints, partial hip joints, joints for large trochanteric fracture, Moore hip prosthesis, and customized artificial hip joints for individual tumor patients; artificial knee joint, such as artificial knee replacement joint, revision knee replacement system, restricted artificial knee joints, and customized artificial knee joints for individual tumor patients; and spine products consisting of vertebral fixation devices. It also provides injury and other orthopedic products comprise orthopedic internal fixation, bone plates, bone nails, bone pins, and bone screws; OEM products, such as orthopedic internal fixation; and lamb salvage systems. In addition, the company offers orthopedic surgical equipment and its manufacturing equipment; and special metal and plastic materials, as well as imports and exports its products. It serves in Taiwan, Asia, the Americas, Europe, Africa, and Australia. The company was incorporated in 1993 and is headquartered in New Taipei City, Taiwan. United Orthopedic Corporation is a subsidiary of Chi-Yi Investment Co. Ltd.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||